PMID- 10963116
OWN - NLM
STAT- MEDLINE
DCOM- 20010125
LR  - 20180604
IS  - 0213-3911 (Print)
IS  - 0213-3911 (Linking)
VI  - 15
IP  - 3
DP  - 2000 Jul
TI  - Immunohistochemical expression of retinoblastoma gene product (Rb), p53 protein, 
      MDM2, c-erbB-2, HLA-DR and proliferation indices in human urinary bladder 
      carcinoma.
PG  - 721-7
LID - 10.14670/HH-15.721 [doi]
AB  - Archival biopsy specimens from transitional cell bladder cancers (n=88) were 
      analysed immunohistochemically for the expression of the retinoblastoma (Rb) gene 
      protein, p53, mdm2, c-erbB-2, HLA-DR antigen and proliferation indices. An 
      altered nuclear expression of Rb, p53 and mdm2 was observed in 55.2%, 33.3% and 
      18.2% of tumors respectively. Cytoplasmic membrane immunoreactivity (>25% tumor 
      cells) for c-erbB-2 was detected in 14.1% of tumors and aberrant HLA-DR antigen 
      cytoplasmic staining (>5% of tumor cells) in 22.2% of the cases. P53 
      overexpression was associated with higher tumor grade and stage. Aberrant HLA-DR 
      antigen expression and PCNA were also correlated with the grade of 
      differentiation and tumor stage. MIB1 was statistically correlated with stage. 
      pRb scores and HLA-DR antigen expression were correlated with proliferation 
      activity as determined by PCNA and MIB1 immunostaining. p53 protein was also 
      strongly correlated with the proliferation index PCNA. A strong correlation 
      between PCNA and MIB1 (p<0.0001) was also found. In addition a statistically 
      positive correlation between p53 and HLA-DR antigen expression was observed. Our 
      data show that, although pRb and p53 protein expressions are not associated 
      between them, they may contribute to the growth fraction of the bladder cancer. 
      In addition, p53 and HLA-DR antigen expression could be indicators of aggressive 
      behavior of bladder cancer.
FAU - Ioachim, E
AU  - Ioachim E
AD  - Department of Pathology, Medical School, University of Ioannina, Greece. 
      nagnanti@cc.uoi.gr
FAU - Charchanti, A
AU  - Charchanti A
FAU - Stavropoulos, N E
AU  - Stavropoulos NE
FAU - Skopelitou, A
AU  - Skopelitou A
FAU - Athanassiou, E D
AU  - Athanassiou ED
FAU - Agnantis, N J
AU  - Agnantis NJ
LA  - eng
PT  - Journal Article
PL  - Spain
TA  - Histol Histopathol
JT  - Histology and histopathology
JID - 8609357
RN  - 0 (Antigens, Nuclear)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (HLA-DR Antigens)
RN  - 0 (Nuclear Proteins)
RN  - 0 (Proliferating Cell Nuclear Antigen)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 0 (Retinoblastoma Protein)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - EC 2.3.2.27 (MDM2 protein, human)
RN  - EC 2.3.2.27 (Proto-Oncogene Proteins c-mdm2)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antigens, Nuclear
MH  - Biomarkers, Tumor
MH  - Female
MH  - HLA-DR Antigens/*biosynthesis
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Male
MH  - Middle Aged
MH  - Nuclear Proteins/biosynthesis
MH  - Proliferating Cell Nuclear Antigen/*biosynthesis
MH  - Proto-Oncogene Proteins/*biosynthesis
MH  - Proto-Oncogene Proteins c-mdm2
MH  - Receptor, ErbB-2/*biosynthesis
MH  - Retinoblastoma Protein/*biosynthesis
MH  - Tumor Suppressor Protein p53/*biosynthesis
MH  - Urinary Bladder Neoplasms/*metabolism/pathology
EDAT- 2000/08/30 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/08/30 11:00
PHST- 2000/08/30 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/08/30 11:00 [entrez]
AID - 10.14670/HH-15.721 [doi]
PST - ppublish
SO  - Histol Histopathol. 2000 Jul;15(3):721-7. doi: 10.14670/HH-15.721.